Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbamazepine effect on BI 1810631 pharmacokinetics in healthy males
NCT06028464Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2023
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zongertinib, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 Extrapolated to Infinity at 168 hours and Maximum Measured Concentration of Zongertinib in Plasma at 168 hours. Started Sep 2023; status: completed.
02
Drugs
zongertinib
Beyond the preview
Go deeper on NCT06028464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06028464.